https://doi.org/10.4081/hmr.v1i8.276

Gemtuzumab ozogamicin

Vol. 1 No. 8: New Drugs in Hematology, Bologna, October 9-11, 2005
Published: May 29, 2009
Abstract Views: 153
PDF: 154
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

S.L. Amadori
support@pagepress.org
Treatment outcome for acute myeloid leukemia (AML) has substantially improved over the last decade, especially in patients younger than 60 years of age who can tolerate intensified treatment strategies including hematopoietic stem cell transplantation.1 On the other hand, there has been little progress in the treatment of older patients where intensive chemotherapy regimens are associated with a lower complete remission (CR) rate, an increased risk of relapse and an inferior overall survival.2-3 Factors which have been considered important in explaining the adverse effect of age include: 1) reduced ability of older patients to withstand the morbidity associated with chemotherapy-induced marrow hypoplasia; 2) concurrent medical problems; 3) unfavourable biologic profile of the disease as documented by a high proportion of patients presenting with adverse cytogenetics, preexisting myelodysplasia, stem cell and chemoresistant phenotype.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Amadori, S. (2009). Gemtuzumab ozogamicin. Hematology Meeting Reports (formerly Haematologica Reports), 1(8). https://doi.org/10.4081/hmr.v1i8.276
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).